Wedbush Predicts Lower Earnings for Artiva Biotherapeutics

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Wedbush decreased their FY2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report released on Wednesday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($5.08) per share for the year, down from their prior forecast of ($4.55). Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.60) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.76) EPS and FY2027 earnings at ($2.91) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Several other research analysts have also recently issued reports on ARTV. Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective on the stock. TD Cowen assumed coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating on the stock. Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Buy” and an average target price of $21.25.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $10.06 on Friday. The firm has a 50-day moving average of $12.57. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of the stock. Barclays PLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $304,000. State Street Corp purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth about $1,337,000. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $42,000. Charles Schwab Investment Management Inc. acquired a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $623,000. Finally, Wellington Management Group LLP purchased a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.